Core Viewpoint - Tianjin Tasly Pharmaceutical Co., Ltd. (600535.SH) announced that its wholly-owned subsidiary, Tasly Biopharmaceuticals Co., Ltd., received approval from the National Medical Products Administration for a new indication of its innovative biological drug, Recombinant Human Urokinase (Puyouke), for thrombolytic treatment of acute ischemic stroke [1] Group 1 - The drug Puyouke is a Class 1 innovative biological drug that was supported by the "Major New Drug Creation" technology major project during the "Eleventh Five-Year Plan" period [1] - This new indication for acute ischemic stroke is the second approved indication for the drug in China, following its initial approval for acute ST-segment elevation myocardial infarction [1]

普佑克作为国内目前唯一获批上市的重组人尿激酶原产品，也是首个获批"十一五"规划期间国家"重大 新药创制"科技重大专项支持下的1类生物创新药。该药已上市适应症为急性ST段抬高型心肌梗死，本 次新增急性缺血性脑卒中溶栓治疗适应症的获批丰富了公司神经/精神领域产品线，进一步拓展了产品 目标患者人群，有利于提升公司及产品市场竞争力。 天士力（600535）(600535.SH)发布公告，近日，公司全资子公司天士力生物医药股份有限公司(简称"天 士力生物")收到国家药品监督管理局核准签发的《药品注册证书》，批准公司拥有自主知识产权的生物 创新药注射用重组人尿激酶原(普佑克)新增适应症，用于急性缺血性脑卒中的溶栓治疗。普佑克是"十 一五"规划期间国家"重大新药创制"科技重大专项支持下获批的1类生物创新药(急性ST段抬高型心肌梗 死适应症)，本次急性缺血性脑卒中适应症是该药在国内获批的第二个适应症。 ...

Core Viewpoint - Tianjin Tasly Pharmaceutical has received approval from the National Medical Products Administration for its product, recombinant human urokinase (Puyouke), to be used for thrombolytic treatment of acute ischemic stroke, expanding its product line in the neurology/psychiatry sector [1] Group 1 - The company’s wholly-owned subsidiary, Tasly Biopharmaceuticals, has been granted a drug registration certificate for Puyouke, which is the only approved recombinant human urokinase product in China [1] - Puyouke was previously approved for the treatment of acute ST-segment elevation myocardial infarction, and the new indication for acute ischemic stroke enhances the company's offerings in the neurological field [1] - This product is recognized as a Class 1 innovative biological drug supported by the "Major New Drug Creation" project during the "11th Five-Year Plan" period [1]

Core Viewpoint - Tianjin Tasly Pharmaceutical Group Co., Ltd. has received approval from the National Medical Products Administration for a new indication of its innovative biological drug, recombinant human urokinase (Puyouke), for thrombolytic treatment of acute ischemic stroke [1] Company Summary - Tasly's subsidiary, Tasly Biopharmaceuticals, has been granted a drug registration certificate for the new indication, marking the second approved indication for Puyouke in China [1] - The drug was developed under the "Major New Drug Creation" program during the 11th Five-Year Plan and is classified as a Class 1 innovative biological drug [1] - As of the latest report, Tasly's market capitalization stands at 23.5 billion yuan [1] Revenue Composition - For the year 2024, Tasly's revenue composition is as follows: Traditional Chinese medicine accounts for 70.89%, chemical drugs for 15.38%, pharmaceutical commerce for 10.53%, biological drugs for 2.25%, and chemical raw materials for 0.61% [1]

天士力公告，全资子公司天士力生物医药股份有限公司收到国家药品监督管理局核准签发的《药品注册 证书》，批准注射用重组人尿激酶原（普佑克）新增适应症，用于急性缺血性脑卒中的溶栓治疗。普佑 克是国内首个获批的1类生物创新药，本次新增适应症丰富了公司神经/精神领域产品线，有利于提升公 司及产品市场竞争力。 ...

Core Viewpoint - The trend of "deposit migration" among residents and companies is highlighted, with a significant decrease in resident deposits and an increase in wealth management products due to lower deposit rates and a recovering equity market [1][2]. Group 1: Deposit Trends - In August, new resident deposits decreased by 110 billion yuan, down 600 billion yuan year-on-year, while new non-bank deposits increased by 11.8 billion yuan, up 5.5 billion yuan year-on-year [1]. - The overall scale of listed companies' wealth management has shown a downward trend, with a total subscription amount of 1.10 trillion yuan in the past year, a decrease of 26.17% from the peak of 1.49 trillion yuan in 2022 [2]. Group 2: Wealth Management Preferences - Listed companies are increasingly favoring wealth management products, with a notable shift towards structured deposits and bank wealth management products, which now account for 9.93%, 6.87%, and 2.07% of their investments, respectively [2][4]. - The demand for wealth management among listed companies is driven by the need for stable returns and liquidity, especially as companies mature and experience cash accumulation [3]. Group 3: Market Dynamics - The decline in deposit rates has made bank wealth management products more attractive, with average annualized yields for cash management products at 1.32% and long-term fixed income products at 1.39% [6][7]. - The total investment in structured deposits by listed companies was approximately 681.12 billion yuan, although this has decreased by around 100 billion yuan year-on-year [7]. Group 4: Corporate Financial Strategies - Companies are increasingly focusing on optimizing their capital structure and improving asset return efficiency, necessitating flexible management of idle funds to mitigate liquidity risks [5]. - The recovery in corporate profits is expected to lead to a restoration of the total scale of funds used for wealth management, as net profits for all A-share listed companies rose to 3.21 trillion yuan in the first half of 2025, up 2.23% year-on-year [8]. Group 5: Asset Management Opportunities - Asset management institutions are actively positioning themselves to meet the growing demand for corporate wealth management, with a focus on customized and flexible product offerings [9][10]. - The trend towards institutionalization and professionalization in the listed company wealth management market presents significant opportunities for asset management firms to enhance their competitive capabilities [11].

1、关于使用闲置资金购买银行理财产品的议案 内容详见公司在上海证券交易所网站（www.sse.com.cn）发布的《关于使用闲置资金购买银行理财产品 的公告》（公告编号：临2025-062号）。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600535 证券简称：天士力 编号：临2025-061号 天士力医药集团股份有限公司 第九届董事会第14次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 天士力医药集团股份有限公司（以下简称"公司"）第九届董事会第14次会议通知于2025年9月12日以书 面方式发出，会议于2025年9月17日下午13:30在公司会议室以现场会议方式召开，会议应到董事15人， 实到13人，董事王亮先生因工作原因书面委托董事王克先生代为行使表决权，董事原京先生因工作原因 书面委托董事席凯先生代为行使表决权，公司部分高管列席会议。会议符合《公司法》和《公司章程》 的有关规定，会议合法、有效。会议由公司董事长周辉女士主持，经与会人员逐项审议，通过了以下议 案： 表决情况为：有效 ...

证券代码：600535 证券简称：天士力 编号：临2025-062号 天士力医药集团股份有限公司 关于使用闲置资金购买银行理财产品的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 基本情况 | 投资金额 | 不超过 亿元人民币 30 | | --- | --- | | 投资种类 | 银行及其下属理财子公司中低风险收益型理财产品（产品类型为 | | | 固定收益类非保本浮动收益型，风险评级为R2以内产品（含R2）） | | | 和银行结构性存款，资金不会直接投资证券市场产品股票、债券、 | | | 基金、外汇及其衍生产品等高风险产品。 | | 资金来源 | 自有资金 | 已履行及拟履行的审议程序 天士力医药集团股份有限公司（以下简称"公司"）于 2025 年 9 月 17 日召 开第九届董事会第 14 次会议，审议通过了《关于使用闲置资金购买银行理财产品 的议案》，本议案尚需提交公司股东大会审议。 特别风险提示 公司拟购买的理财产品虽为中低风险收益型理财产品和银行结构性存款，但金 融市场受宏观经济、财 ...

召开地点：天津市北辰科技园区天士力现代中药城天士力医药集团股份有限 公司会议室 证券代码：600535 证券简称：天士力 编号：临2025-063号 天士力医药集团股份有限公司 关于召开2025年第五次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一)股东大会类型和届次 2025年第五次临时股东大会 召开的日期时间：2025 年 10 月 10 日 15 点 30 分 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 10 月 10 日 至2025 年 10 月 10 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互 联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 (六) 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 1 股 ...

内容详见公司在上海证券交易所网站（www.sse.com.cn）发布的《关于召开 2025 年第五次临时股东大会的通知》（公告编号：临 2025-063 号）。 证券代码：600535 证券简称：天士力 编号：临 2025-061 号 天士力医药集团股份有限公司 第九届董事会第 14 次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 天士力医药集团股份有限公司（以下简称"公司"）第九届董事会第 14 次会 议通知于 2025 年 9 月 12 日以书面方式发出，会议于 2025 年 9 月 17 日下午 13:30 在公司会议室以现场会议方式召开，会议应到董事 15 人，实到 13 人，董事王亮 先生因工作原因书面委托董事王克先生代为行使表决权，董事原京先生因工作原 因书面委托董事席凯先生代为行使表决权，公司部分高管列席会议。会议符合《公 司法》和《公司章程》的有关规定，会议合法、有效。会议由公司董事长周辉女 士主持，经与会人员逐项审议，通过了以下议案： 1、关于使用闲置资金购买银行理财产品的议案 内容详见 ...